Related Experiment Video
Updated: May 24, 2026
RNA Isolation from Mouse Ocular Lens Epithelium and Fiber Cell Bulk Masses
Published on: October 10, 2025
KLF6SV1 siRNA inhibits proliferation of human lens epithelial cells
Ying Su1, Yixin Qu, Chenggong Jiang
1Department of Ophthalmology, First clinical college of Harbin Medical University, Harbin, China.
Purpose:
To investigate whether transfection with Krüppel-like factor 6 splice variant 1 (KLF6SV1) siRNA can inhibit proliferation of human lens epithelial cell (HLEC).
Methods:
Plasmid containing KLF6SV1 siRNA was used to decrease the level of KLF6SV1 protein in HLEC. The expression of protein27 kinase inhibition protein 1 (p27(kip1)) and proliferation cell nuclear antigen (PCNA) was tested with western blot. Cell proliferation was assayed by 3-(4,5-dimethylthiazolyl-2-)-2,5-diphenyltetrazoliumbromide (MTT) assay and bromodeoxyuridine (BrdU) incorporation.
Results:
KLF6SV1 siRNA can decrease KLF6SV1 expression which leads to increased levels of p27(kip1) and decreased expression of PCNA in HLEC. Cells transfected with pKLF6SV1 siRNA showed less viability compared with the control group in vitro.
Conclusions:
KLF6SV1 siRNA can effectively inhibit HLEC proliferation. It can be regarded as a novel target to treat posterior capsular opacity (PCO).
Insights
Krüppel-like factor 6 splice variant 1 (KLF6SV1) siRNA effectively inhibits human lens epithelial cell (HLEC) proliferation. This finding presents KLF6SV1 siRNA as a potential therapeutic target for posterior capsular opacity (PCO).
Area of Science:
- Ophthalmology
- Molecular Biology
- Cell Biology
Background:
- Posterior capsular opacity (PCO) is a common complication after cataract surgery.
- Understanding the molecular mechanisms regulating lens epithelial cell proliferation is crucial for PCO prevention and treatment.
Purpose of the Study:
- To investigate the effect of Krüppel-like factor 6 splice variant 1 (KLF6SV1) siRNA on human lens epithelial cell (HLEC) proliferation.
- To determine if KLF6SV1 is a viable therapeutic target for PCO.
Main Methods:
- HLEC were transfected with a plasmid encoding KLF6SV1 siRNA to reduce KLF6SV1 protein levels.
- Western blot analysis was used to assess the expression of p27(kip1) and PCNA.
- Cell proliferation was quantified using MTT assays and BrdU incorporation.
Main Results:
- KLF6SV1 siRNA effectively reduced KLF6SV1 expression in HLEC.
- Transfection with KLF6SV1 siRNA led to increased p27(kip1) levels and decreased PCNA expression.
- In vitro studies showed reduced HLEC viability in cells transfected with KLF6SV1 siRNA compared to controls.
Conclusions:
- KLF6SV1 siRNA demonstrates significant inhibitory effects on HLEC proliferation.
- KLF6SV1 emerges as a promising molecular target for therapeutic strategies aimed at treating PCO.
